



US006943166B1

(12) **United States Patent**
Pullman et al.

(10) **Patent No.:** **US 6,943,166 B1**
(45) **Date of Patent:** **Sep. 13, 2005**

(54) **COMPOSITIONS COMPRISING
PHOSPHODIESTERASE INHIBITORS FOR
THE TREATMENT OF SEXUAL
DISFUNCTION**

(75) Inventors: **William Ernest Pullman**, Far Hills, NJ
(US); **John Steven Whitaker**,
Woodinville, WA (US)

(73) Assignee: **Lilly ICOS LLC.**, Wilmington, DE
(US)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

(21) Appl. No.: **10/031,556**

(22) PCT Filed: **Apr. 26, 2000**

(86) PCT No.: **PCT/US00/11129**

§ 371 (c)(1),

(2), (4) Date: **Oct. 19, 2001**

(87) PCT Pub. No.: **WO00/66099**

PCT Pub. Date: **Nov. 9, 2000**

Related U.S. Application Data

(60) Provisional application No. 60/132,036, filed on Apr. 30,
1999.

(51) **Int. Cl.**⁷ **A61K 31/495**; A61K 31/50

(52) **U.S. Cl.** **514/250**

(58) **Field of Search** 514/250

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,859,006 A 1/1999 Daugan 514/249

6,140,329 A * 10/2000 Daugan 514/250

6,451,807 B1 9/2002 Emmick et al.

FOREIGN PATENT DOCUMENTS

WO	WO 95/19978	7/1995	C07D/471/14
WO	WO 97/03675	2/1997	A61K/31/495
WO	WO 99 59584	11/1999		
WO	WO 99/59584	11/1999	A61K/31/415
WO	WO 00 53148	9/2000		
WO	WO 00 66114	11/2000		
WO	WO 01 80860	11/2001		

OTHER PUBLICATIONS

Israel, *The Pharmaceutical Journal*, 261, pp. 164–165
(1998).

Goldenberg, *Clinical Therapeutics*, 20, No. 6, pp.
1033–1048 (1998).

WPIOS AN 2000–339026, Furitsu et al, JP 19990276134,
Sep. 1999, abstract.

NDA 20–895 (New Drug Application) Sildenafil for Male
Impotence, pp. 99–103 and 183–187, Jan. 22, 1998, author
unknown.

* cited by examiner

Primary Examiner—Rebecca Cook

(74) *Attorney, Agent, or Firm*—Marshall, Gerstein & Borun
LLP

(57) **ABSTRACT**

The present invention relates to highly selective phosphodi-
esterase (PDE) enzyme inhibitors and to their use in phar-
maceutical articles of manufacture. In particular, the present
invention relates to potent inhibitors of cyclic guanosine
3',5'-monophosphate specific phosphodiesterase type 5
(PDE5) that when incorporated into a pharmaceutical prod-
uct at about 1 to about 20 mg unit dosage are useful for the
treatment of sexual dysfunction.

12 Claims, No Drawings